IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
The Efficacy of 308-nm Monochromatic Excimer light and 0.1% Topical Tacrolimus in the treatment of Vitiligo

Author: , SHOKHAN ALI ABDULLAH*, MOHAMMED YOUSIF SAEED
Abstract: Background and objectives: Vitiligo is an acquired chronic skin disease characterized by circumscribed depigmented macules and patches. Our aim is to evaluate the efficacy of combined therapy of 308-nm Monochromatic Excimer light (MEL) with 0.1% topical tacrolimus, versus 308-nm MEL alone in treating vitiligo. Methods: In this study thirty patients, with Fitzpatrick skin types III to IV, aged 12 to 57 years were recruited to take part. Eighty symmetrical vitiliginous patches at different body sites were selected and divided equally into two groups A and B. Each group treated with 308-nm MEL twice weekly for total of 30 sessions. Topical tacrolimus 0.1% added concurrently to group A and applied twice daily on a targeted lesion throughout the study. Results: Lesions located on face and trunk in group A 9.31% achieved complete repigmentation versus 47.8% in group B. Lesions located on extremities and acral area in group A 47.1% were achieved 50 – 74% repigmentation, whereas in group B 11.8% of lesions achieved 50-74% repigmentation. Furthermore, in group A, 5 patches (29.4%) in acral area were unresponsive to treatment, versus 8 patches (47.1%) in group B were lacking response to the treatment. Conclusion: The outcome of this study concluded that combined therapy of 308-nm MEL with a topical tacrolimus 0.1% is more preferable to MEL alone in treatment of vitiligo, especially in lesion’s localized in UV sensitive area (face and trunk). Moreover, the combination therapy remains superior to monotherapy in more resistant anatomical sites (Acral and bony prominence).
Keyword: 308-nm; combination; monochromatic; excimer; vitiligo; tacrolimus.
DOI: https://doi.org/10.31838/ijpr/2019.11.02.106
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477